11.12. 2012 BioTurku®

Biotie's tozadenant meets primary and multiple secondary endpoints in phase 2b study in Parkinson's disease

In Turku Science Park operating Biotie Therapies Corp. has reported top-line data from a Phase 2b study evaluating its adenosine A2a antagonist tozadenant (SYN115) in Parkinson's disease (PD) patients experiencing levodopa related end of dose wearing off. The study met its primary endpoint of a statistically highly significant decrease in 'off' time vs. placebo, as well as demonstrating efficacy across multiple secondary endpoints.

In the 420 patient study, tozadenant displayed clinically relevant and statistically highly significant effects on PD across multiple pre-specified evaluation metrics including: a decrease vs. placebo in 'off' time, an increase in 'on' time, an improved score on UPDRS part III  and UPDRS parts I-III combined, as well as improvements on clinician- and patient-assessed global impression scores. Additionally, the study identified the minimally efficacious and maximum feasible dose levels, as well as clinically useful target doses for Phase 3. Tozadenant was generally well tolerated in the study. "This trial met all the objectives to be expected of a Phase 2 study", said Dr. Stephen Bandak, CMO of Biotie Therapies Corp.

"We are extremely pleased with the results of this study", said Timo Veromaa, President and CEO of Biotie Therapies Corp. "The rigor with which the study was conducted also makes us optimistic that it may be considered a pivotal study within the envisioned development program. We look forward to analyzing the results in detail with our license partner UCB and expect a decision from UCB in the first quarter of 2013 regarding the next steps."

About tozadenant

Tozadenant is an oral, potent and selective adenosine A2a receptor antagonist, which enters the brain and modulates regions associated with motor and non-motor function. Biotie holds a license from Roche for development and commercialization of tozadenant in all indications.

Biotie has granted UCB Pharma S.A. a license for exclusive, worldwide rights to tozadenant. Pending evaluation of the results of the now completed Phase 2b study, UCB will be responsible for conducting the Phase 3 program and commercializing tozadenant. UCB is expected to take a decision about this in the first quarter of 2013.

About Parkinson's disease

Parkinson's disease is the second most common neurodegenerative disorder, after Alzheimer's disease. It affects about one percent of people ages 65-69, rising to up to three percent of people who are 80 years and older. The symptoms of Parkinson's disease result from decreased dopamine production in regions of the brain controlling movement.

About Biotie

Turku based Biotie is a specialized drug development company focused on the development of drugs for neurodegenerative and psychiatric disorders (e.g. Parkinson's disease, Alzheimer's disease and other cognitive disorders, alcohol and drug dependence (addiction) and post-traumatic stress disorder), and inflammatory and fibrotic liver disease. The company has a strong and balanced development portfolio with several innovative small molecule and biological drug candidates at different stages of clinical development. Biotie's products address diseases with high unmet medical need and significant market potential.

Biotie has a strategic collaboration with UCB Pharma S.A. covering tozadenant for Parkinson's disease. The Marketing Authorization Application for Biotie's most advanced product, SelincroTM (nalmefene) for alcohol dependence was filed in the EU by our partner H. Lundbeck A/S and was accepted for review by the European Medicines Agency in December 2011. Biotie shares are listed on NASDAQ OMX Helsinki Ltd.